Shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) saw unusually-strong trading volume on Wednesday . Approximately 1,386,051 shares changed hands during trading, an increase of 63% from the previous session’s volume of 847,945 shares.The stock last traded at $2.02 and had previously closed at $1.96.

A number of equities analysts have weighed in on DNAI shares. Zacks Investment Research lowered shares of ProNAi Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 15th. Wedbush lowered shares of ProNAi Therapeutics from an “outperform” rating to a “neutral” rating in a research report on Monday, June 6th. SunTrust Banks Inc. lowered shares of ProNAi Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $25.00 to $4.00 in a research report on Monday, June 6th. Finally, Jefferies Group lowered shares of ProNAi Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the company from $22.00 to $4.50 in a research report on Monday, June 6th.

The stock’s market capitalization is $57.62 million. The company’s 50-day moving average price is $1.98 and its 200-day moving average price is $4.51.

ProNAi Therapeutics (NASDAQ:DNAI) last posted its quarterly earnings results on Friday, August 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.05. Equities research analysts predict that ProNAi Therapeutics Inc. will post ($1.32) EPS for the current fiscal year.

An institutional investor recently raised its position in ProNAi Therapeutics stock. RS Investment Management Co. LLC raised its position in ProNAi Therapeutics Inc. (NASDAQ:DNAI) by 12.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 699,794 shares of the company’s stock after buying an additional 76,550 shares during the period. RS Investment Management Co. LLC owned about 2.33% of ProNAi Therapeutics worth $10,525,000 as of its most recent filing with the SEC.

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.